Veraxa Biotech is focused on developing advanced cancer therapeutics through innovative technologies, particularly in the realm of antibody-drug conjugates (ADCs) and bispecific antibodies. Their ADC technology emphasizes the importance of identifying the right antibodies for specific diseases and utilizing bioengineering techniques to optimize the positioning of therapeutic payloads. This approach is complemented by their proprietary microfluidic platform, which enables the functional screening of antibodies against a wide range of targets, thereby enhancing the efficacy and safety of their therapeutic candidates. Veraxa's commitment to improving patient outcomes is evident in their goal to create treatments that minimize side effects while maximizing therapeutic effectiveness.

A key innovation from Veraxa is their BiTAC technology, which stands for bi-targeted tumor-associated cytotoxicity. This platform allows for the development of bispecific antibodies that can engage two different target molecules simultaneously, enhancing the precision of cancer therapies. By splitting the therapeutic molecule into two complementary parts, Veraxa aims to activate the therapeutic effect only in the presence of both components at the tumor site, thereby reducing off-target toxicity. This combinatorial-gated design not only applies to T-cell engagers but also extends to next-generation ADCs, promising a new era of safer and more effective cancer treatments.

Germany

VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation. Through biochemical and technological innovation, we strive to transform the way antibodies and antibody-drug conjugates (ADCs) are created to develop more effective and safe therapies for patients.

With our transformative technologies, we can streamline and derisk early bioconjugate development. We have established a rich pipeline of proprietary ADCs and are collaborating with a number of partners to provide access to our unique research & development capabilities going from target to antibody to ADC.

Veraxa Biotech

Company Details